AI English summary of an SEC filing — figures as filed
Biogen BIIBBiogen said it entered into a merger agreement with Apellis Pharmaceuticals on March 31, 2026 and plans to launch a tender offer for Apellis common stock at $41.00 per share in cash, plus 1 contingent value rights (CVRs) per share that could pay up to $4.00 in cash in total.
Key points
AI summaryBiogen said it entered into a merger agreement with Apellis Pharmaceuticals on March 31, 2026 and plans to launch a tender offer for Apellis common stock at $41.00 per share in cash, plus 1 contingent value rights (CVRs) per share that could pay up to $4.00 in cash in total.
The company said the CVRs would pay $2.00 per CVR if annual net sales of SYFOVRE and related products reach at least $1,500,000,000, and $2.00 per CVR if annual net sales reach at least $2,000,000,000. It said that if the first milestone is not achieved by December 31, 2030 but the second is achieved in 2031, the second milestone payment would be $4.00 per CVR.
Biogen said the tender offer will remain open for 20 business days and is subject to conditions including a minimum tender of more than 50% of Apellis’ outstanding shares and the expiration of HSR Act waiting periods. It said the offer is not subject to a financing condition. The parties may terminate the agreement if the offer is not completed by September 30, 2026, and Apellis would pay a termination fee of $205,000,000 in certain circumstances.
Biogen said the Apellis board unanimously recommended that stockholders tender their shares in the offer. It also said certain Apellis directors and officers, including Cedric Francois, and Morningside Venture Investments entered into support agreements to tender all of their shares in the offer. It said these holders owned about 14% of Apellis’ outstanding shares as of March 27, 2026.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Biogen to acquire Apellis for $41.00 cash plus CVRs up to $4.00
Biogen said it entered into a merger agreement with Apellis Pharmaceuticals on March 31, 2026 and plans to launch a tender offer for Apellis common stock at $41.00 per share in cash, plus 1 contingent value rights (CVRs) per share that could pay up to $4.00 in cash in total.
Source · Based on the filing body and exhibits
CVR Milestones: SYFOVRE Annual Net Sales of $1,500,000,000 and $2,000,000,000
The company said the CVRs would pay $2.00 per CVR if annual net sales of SYFOVRE and related products reach at least $1,500,000,000, and $2.00 per CVR if annual net sales reach at least $2,000,000,000. It said that if the first milestone is not achieved by December 31, 2030 but the second is achieved in 2031, the second milestone payment would be $4.00 per CVR.
Source · Based on the filing body and exhibits
Tender Offer Conditions, Outside Date and Termination Fee of $205,000,000
Biogen said the tender offer will remain open for 20 business days and is subject to conditions including a minimum tender of more than 50% of Apellis’ outstanding shares and the expiration of HSR Act waiting periods. It said the offer is not subject to a financing condition. The parties may terminate the agreement if the offer is not completed by September 30, 2026, and Apellis would pay a termination fee of $205,000,000 in certain circumstances.
Source · Based on the filing body and exhibits
Apellis Board Recommends and Support Agreements Cover About 14%
Biogen said the Apellis board unanimously recommended that stockholders tender their shares in the offer. It also said certain Apellis directors and officers, including Cedric Francois, and Morningside Venture Investments entered into support agreements to tender all of their shares in the offer. It said these holders owned about 14% of Apellis’ outstanding shares as of March 27, 2026.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…